Purpose Hyperglycemia is the major risk factor for microvascular complications in type 2
diabetes mellitus (T2DM) patients. This randomized controlled clinical trial aimed to …

Cardiovascular disease is the leading cause of death globally among non-communicable
diseases, which imposes a serious socioeconomic burden on patients and the healthcare …

Purpose Dipeptidyl peptidase 4 (DPP4) is one of the newly identified adipokines, which acts
as paracrine in adipose tissue and as endocrine hormones in the liver, muscles and central …

The objective of the review led to the pursuit of adopting dipeptidyl peptidase-4 inhibitors
(DPP4i) as a novel pharmacotherapy in diabetes mellitus (DM) and cardiorenal syndrome …

Abstract Context Dipeptidylpeptidase (DPP)-4 is a key regulator of the incretin system. It
exists in a membrane-bound form and a soluble form (sDPP-4). Initial human studies …

Background The dipeptidyl peptidase-4 (DPP4) enzyme is a novel adipokine potentially
involved in the development of the metabolic syndrome (MetS). Previous observations …

Abstract Aims Dipeptidyl peptidase-4 (DPP4) inhibitors are a novel class of antidiabetic
medication in the treatment of type 2 diabetes mellitus. Several studies have indicated that …

Dipeptidyl peptidase-4 (DPP4) is a serine protease that rapidly inactivates the incretin
peptides, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptide to …

Dipeptidyle peptidase (DPP4) is the enzyme which is known to break down two gut
hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic …

Background: Evidence showed that abnormal alteration of adipokines level may perform a
key role in polycystic ovary syndrome (PCOS) pathogenesis. Dipeptidyl peptidase-4 (DPP4) …